Skip to main content

Table 2 Clinical course and outcome according to coagulation status: Group I (low anticoagulation status) included patients with both INR below 2.0 and aPTT ratio below 1.50; Group II (adequate anticoagulation status) included patients with either INR ≥ 2.0 or aPTT ratio ≥ 1.50

From: Thromboembolic stroke in patients with a HeartMate-II left ventricular assist device – the role of anticoagulation

  Overall (n = 38) Coagulation status at the time of event Coagulation status two weeks prior of event
  N (%) Group I (n = 12) Group II (n = 26) p Group I (n = 8) Group II (n = 30) p
Complications        
 Tamponade 6 (16 %) 0 6 (23 %) .15 1 (13 %) 5 (17 %) .99
 Rethoracothomy 7 (18 %) 0 7 (27 %) .07 1 (13 %) 6 (20 %) .99
 Infection 9 (24 %) 2 (17 %) 7 (27 %) .69 2 (25 %) 7 (23 %) .99
 GI bleeding 2 (5 %) 0 2 (8 %) .99 0 2 (7 %) .99
 RV failure 8 (21 %) 2 (17 %) 6 (23 %) .99 2 (25 %) 6 (20 %) .99
 AKI 2 (5 %) 1 (8 %) 1 (4 %) .54 1 (13 %) 1 (3 %) .38
Median duration of follow-up in days (Q1-Q3) 275 (75–522) 299 242 .94 314 254 .96
Median duration of LVAD support in days (Q1-Q3) 279 (134–540) 321 279 .96 314 279 .97
Death before transplant 4 (11 %) 1 (8 %) 3 (12 %) .99 1 (13 %) 3 (10 %) .99
Transplanted and alive 9 (24 %) 2 (17 %) 7 (27 %) .69 1 (13 %) 8 (27 %) .65
Transplanted and deceased 1 (3 %) 0 1 (4 %) .99 0 1 (3 %) .99
Weaned from LVAD 3 (8 %) 0 3 (12 %) .54 1 (13 %) 2 (7 %) .99
On-going LVAD support 21 (55 %) 9 (75 %) 12 (46 %) .16 5 (63 %) 16 (53 %) .71
Thromboembolic stroke 6 (16 %) 2 (17 %) 4 (15 %) .99 0 (0 %) 6 (20 %) <.001
Stroke rate during LVAD support (event/patient/year) .160 .169 .156 .99 - .173 <.001